This trial is active, not recruiting.

Condition adult subjects with anal fissures.
Treatment diltiazem hydrochloride cream and oral diltiazem
Phase phase 1
Sponsor Ventrus Biosciences, Inc
Start date February 2013
End date July 2013
Trial size 12 participants
Trial identifier NCT01816191, VEN307-PK-001


The study is a single-center, open-label, safety and pharmacokinetic study in12 adult subjects with Anal Fissures. Subjects will be screened to determine eligibility within 7 days of treatment. There will be three parts to the study and all subjects will participate in each part.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification pharmacokinetics study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Topical cream and oral pill
diltiazem hydrochloride cream and oral diltiazem

Primary Outcomes

Single and multiple dose Pharmacokinetic parameters
time frame: up to 6 months after enrollment begins

Secondary Outcomes

Safety as determined by nature, severity and relationship of adverse events, clinical labs, physical exam findings, vital signs and Electrocardiogram
time frame: Up to 6 months after enrollment begins

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Subjects with evidence of a circumscribed anal fissure, with induration at the edges. - Any female of non-childbearing potential who: a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post-menopausal (demonstration of total cessation of menses for ≥ 1 year from the date of the screening visit). - Any female of child bearing potential must agree to use at least one form of contraception(may be a barrier method), during the full duration of the study. - Able to communicate adequately with the investigator and to comply with the requirements for the entire study. - Capable of and freely willing to provide written informed consent prior to participating in the study. Exclusion Criteria: - Unwilling to have visual or medical examination of the Anal Fissure. - More than 1 Anal Fissure. - Subjects with Anal Fissure associated with or caused by other conditions, including but not limited to: drug-induced, trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy. - Unwilling to stop all other concomitant topical preparations applied in and around the anus from Day -1 through end of the study. - Use of sitz bath from signing of ICF (Informed Consent Form) to end of study. - Use of anesthetics from signing the ICF to end of study. - Subfissure injection of botulinum toxin in the 3 months prior to signing the ICF. - Known sensitivity to investigational product(s) or calcium channel blockers. - Active treatment with anti-viral therapies for HIV (e.g. indinavir, nelfinivir,ritonavir). 10. Treatment with any prohibited medications within 14 days prior to signing the ICF: - Cytochrome P450 (CYP450) inhibitors and inducers - Cytochrome P3A4 (CYP3A4) substrates, inhibitors, and inducers - Benzodiazepines - β-adrenoceptor antagonists (Beta-Blockers) - Calcium channel blockers - Digoxin - Investigational agents - Opioids - Following concomitant disease state: - Sick sinus syndrome except in the presence of a functioning ventricular pacemaker. - Second-or third-degree Atrioventricular block except in the presence of a functioning ventricular pacemaker. - Hypotension (less than 90 mm Hg systolic). - Acute myocardial infarction and pulmonary congestion documented by x-ray. - History of clinically significant renal disease. - History of clinically significant Alzheimer's or Parkinson's disease. - History of clinically significant hepatic disease. - Current infection treated with a macrolide antibiotic. - Clinical evidence or history of fecal incontinence. - Clinical evidence or history of anal fistula. - Clinical evidence or history of anal abscess. - History of inflammatory bowel disease (e.g. Crohn's disease, Ulcerative Colitis). - History of any prior anal or rectal surgery including but not limited to: lateral sphincterotomy and anal stretch. - History of radiation therapy to the pelvis. - Fixed anal stenosis/fibrosis. - Major organ transplant. - Any clinically significant laboratory abnormalities during screening. - BMI > 40 kg/m2. - Malignancy within 5 years prior to randomization (with the exception of treated basal cell/squamous cell carcinoma of the skin). - Any disease or prior/planned surgery that may interfere with the subject successfully completing the study. - Currently using narcotic(s) chronically. - Breast-feeding females. - Employees, family members, or students of the investigator or clinical site.

Additional Information

Official title An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride
Trial information was received from ClinicalTrials.gov and was last updated in August 2013.
Information provided to ClinicalTrials.gov by Ventrus Biosciences, Inc.